Literature DB >> 6679872

Complement polymorphism, the major histocompatibility complex and associated diseases: a speculation.

R R Porter.   

Abstract

Genes in the major histocompatibility complex code for three major groups of glycoproteins, now referred to as classes I, II, and III. Susceptibility to some autoimmune diseases and to systemic lupus erythematosus is associated with the presence of particular haplotypes of genes in these three classes. An attempt has been made to correlate these finding on the basis of the observation that different polymorphic forms of complement component C4 show varying efficiencies of complement activation. It is suggested that susceptibility to these diseases will be related to the varying efficiency of complement cell lysis and of immune aggregate dissolution by complement. This in turn will depend on the strength of interaction of the different polymorphic forms of C4 with other proteins (some also polymorphic) in the scheme of activation and inactivation of complement. Such an arrangement would lead to preferential association of certain alleles of C2, C4 and factor B and possibly also of class I and II antigens as potential targets of complement reaction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6679872

Source DB:  PubMed          Journal:  Mol Biol Med        ISSN: 0735-1313


  32 in total

1.  Structural differences between the two human complement C4 isotypes affect the humoral immune response.

Authors:  O Finco; S Li; M Cuccia; F S Rosen; M C Carroll
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

Review 2.  The internal thioester and the covalent binding properties of the complement proteins C3 and C4.

Authors:  S K Law; A W Dodds
Journal:  Protein Sci       Date:  1997-02       Impact factor: 6.725

3.  Phenotyping of human complement component C4, a class-III HLA antigen.

Authors:  E Sim; S J Cross
Journal:  Biochem J       Date:  1986-11-01       Impact factor: 3.857

4.  C4B gene polymorphism detected in a human cosmid clone.

Authors:  H L Prentice; P M Schneider; J L Strominger
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

5.  Human C4 polymorphism: pedigree analysis of qualitative, quantitative, and functional parameters as a basis for phenotype interpretations.

Authors:  G Mauff; K Bender; C M Giles; S Goldmann; W Opferkuch; B Wachauf
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

6.  Determining the one, two, three, or four long and short loci of human complement C4 in a major histocompatibility complex haplotype encoding C4A or C4B proteins.

Authors:  Erwin K Chung; Yan Yang; Kristi L Rupert; Karla N Jones; Robert M Rennebohm; Carol A Blanchong; C Yung Yu
Journal:  Am J Hum Genet       Date:  2002-09-10       Impact factor: 11.025

7.  Genetic sophistication of human complement components C4A and C4B and RP-C4-CYP21-TNX (RCCX) modules in the major histocompatibility complex.

Authors:  Erwin K Chung; Yan Yang; Robert M Rennebohm; Marja-Liisa Lokki; Gloria C Higgins; Karla N Jones; Bi Zhou; Carol A Blanchong; C Yung Yu
Journal:  Am J Hum Genet       Date:  2002-09-11       Impact factor: 11.025

8.  Major histocompatibility complex class III genes and susceptibility to immunoglobulin A deficiency and common variable immunodeficiency.

Authors:  J E Volanakis; Z B Zhu; F M Schaffer; K J Macon; J Palermos; B O Barger; R Go; R D Campbell; H W Schroeder; M D Cooper
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

Review 9.  Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosus.

Authors:  Y L Wu; Y Yang; E K Chung; B Zhou; K J Kitzmiller; S L Savelli; H N Nagaraja; D J Birmingham; B P Tsao; B H Rovin; L A Hebert; C Y Yu
Journal:  Cytogenet Genome Res       Date:  2009-03-11       Impact factor: 1.636

Review 10.  Infectious diseases associated with complement deficiencies.

Authors:  J E Figueroa; P Densen
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.